felin
caliciviru
fcv
caus
upper
respiratori
tract
infect
felin
threaten
health
wild
domest
felin
clinic
specif
drug
treat
fcv
yet
develop
igg
extract
inactiv
fcvimmun
hors
sera
equin
f
ab
fragment
obtain
pepsindigest
igg
purifi
prote
column
chromatographi
studi
equin
immunoglobulin
f
ab
fragment
show
effici
neutral
activ
vitro
fcv
therapeut
prophylact
effect
fcvinfect
cat
antifcvspecif
f
ab
fragment
significantli
allevi
clinic
symptom
fcvinfect
cat
reduc
viral
load
trachea
lung
spleen
result
indic
f
ab
fragment
prepar
inactiv
fcvimmun
hors
may
use
prophylact
therapeut
agent
diseas
caus
fcv
felin
caliciviru
fcv
belong
famili
calicivirida
respiratori
pathogen
wide
preval
felin
cat
tiger
cheetah
wild
felin
suscept
kitten
age
day
mainli
infect
mortal
rate
fcv
infect
anim
oral
ulcer
chronic
stomat
rhiniti
conjunct
pneumonia
fcv
distribut
worldwid
highli
contagi
felin
kitten
infect
fcv
prolifer
oral
caviti
upper
respiratori
tract
caus
felin
upper
respiratori
tract
diseas
furtd
clinic
symptom
reliev
day
infect
fcv
still
excret
saliva
nasal
secret
main
reason
substanti
spread
fcv
mani
report
antifcv
drug
recent
year
hongxia
wu
et
al
discov
inhibitori
effect
germacron
licl
fcv
addit
synthet
compound
korea
red
ginseng
extract
krge
ginsenosid
grape
seed
extract
gse
ginger
extract
clove
extract
phaeophyta
extract
also
resist
fcv
past
studi
equin
igg
gradual
favor
research
bloodderiv
biolog
product
easi
obtain
larg
quantiti
low
cost
antibodi
particularli
f
ab
fragment
easi
purifi
larg
quantiti
inexpens
report
prevent
rabi
viru
rv
west
nile
viru
wnv
middl
east
respiratori
syndrom
coronaviru
merscov
ebola
viru
ebov
use
inactivatedfcvimmun
hors
prepar
hyperimmun
serum
extract
igg
thereaft
f
ab
fragment
produc
igg
digest
pepsin
avoid
potenti
allerg
reaction
differ
speci
anim
evalu
protect
effect
equin
igg
vitro
f
ab
fragment
vitro
vivo
fcv
first
determin
neutral
titer
igg
neutral
activ
f
ab
fragment
confirm
indirect
immunofluoresc
neutral
assay
furthermor
infect
cat
treat
purifi
f
ab
fragment
show
significantli
reduc
viral
load
fcv
shed
trachea
lung
lower
score
clinic
symptom
reduc
mortal
cat
immunohistochem
stain
also
confirm
f
ab
reduc
fcv
tissu
result
suggest
equin
neutral
f
ab
fragment
may
protect
cat
fcv
pathogen
infect
cell
infect
fcv
chjl
strain
isol
yanli
zhao
multipl
infect
moi
cultur
supernat
harvest
h
post
infect
frozen
thaw
three
time
inactiv
formaldehyd
cultur
supernat
centrifug
min
remov
cell
debri
clarifi
supernat
ultracentrifug
h
precipit
dissolv
phosphatebuff
salin
pb
ad
sucros
gradient
vari
concentr
three
healthi
black
hors
receiv
multipoint
intramuscular
inject
backsid
mg
fcv
emulsifi
freund
complet
adjuv
first
two
immun
freund
incomplet
adjuv
last
four
immun
week
hors
provid
militari
red
mountain
stud
farm
changchun
china
sera
collect
jugular
vein
week
inject
store
hors
sera
dilut
concentr
pb
satur
ammonium
sulfat
solut
ad
ammonium
sulfat
concentr
solut
allow
stand
h
centrifug
min
remov
supernat
precipit
dissolv
pb
satur
ammonium
sulfat
ad
concentr
ammonium
sulfat
solut
allow
stand
h
centrifug
min
repeat
ammonium
sulfat
step
precipit
dissolv
pb
dialyz
pb
h
remov
ammonium
salt
pepsin
promega
usa
activ
naac
solut
doubledilut
igg
adjust
ph
moll
hcl
final
concentr
iuml
activ
pepsin
ad
dilut
igg
solut
react
h
moll
naoh
ad
adjust
ph
solut
purifi
prote
column
ge
healthcar
usa
purifi
protein
subject
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
follow
coomassi
blue
stain
puriti
f
ab
fragment
analyz
thinlay
chromatographi
scanner
shimadzu
japan
protein
store
use
f
ab
fragment
equin
serum
neutral
titer
detect
fcvinfect
cell
heatinactiv
equin
serum
sampl
purifi
igg
f
ab
dilut
initi
mgml
highest
dose
twofold
serial
dilut
dmem
sigma
usa
fb
gibco
usa
well
column
contain
serial
dilut
sampl
fcv
contain
time
halftissu
cultur
infecti
dose
tcid
ad
column
well
plate
kept
viru
control
contain
dmem
fb
fcv
tcid
suspens
column
well
kept
normal
cell
control
h
cell
suspens
contain
approxim
cell
ad
plate
incub
co
atmospher
final
result
record
neutral
end
point
sampl
calcul
use
reed
muench
formula
monolay
cell
inocul
fcv
moi
healthi
femal
cat
week
old
weigh
kg
randomli
divid
group
cat
cat
purchas
pet
market
changchun
china
investig
prevent
role
f
ab
fcv
infect
anim
cat
per
group
inject
day
day
viral
infect
subcutan
mgkg
purifi
hors
immun
f
ab
equal
volum
normal
hors
f
ab
neg
control
twentyfour
hour
later
day
cat
infect
intranas
fcv
contain
tcid
total
volum
dmem
evalu
therapeut
role
f
ab
fcv
infect
treatment
given
subcutan
day
post
infect
dpi
mgkg
purifi
hors
immun
f
ab
per
cat
control
group
given
equal
volum
normal
hors
f
ab
mock
treatment
clinic
sign
surviv
rate
monitor
anim
bodi
weight
rectal
temperatur
measur
everi
day
dpi
cat
health
rate
day
tabl
detail
viru
titer
oral
swab
detect
quantit
realtim
revers
transcriptionpcr
qrtpcr
cat
group
euthan
dpi
lung
trachea
kidney
liver
spleen
harvest
cat
homogen
ml
pb
tissu
homogen
store
test
viru
load
detect
qrtpcr
express
fig
antifcv
pf
ab
help
prevent
treat
cat
infect
fcv
prevent
group
compar
group
three
group
return
normal
temperatur
earlier
highest
averag
bodi
temperatur
higher
group
differ
signific
p
b
group
weight
fourth
day
began
decreas
averag
bodi
weight
loss
rate
day
significantli
differ
three
group
p
treatment
group
c
compar
group
three
group
return
normal
temperatur
earlier
highest
averag
bodi
temperatur
weight
group
decreas
fourth
day
averag
weight
loss
rate
day
significantli
differ
group
p
e
f
infect
fcv
cat
score
accord
clinic
symptom
score
day
infect
averag
score
prevent
group
treatment
group
group
respect
significantli
differ
three
group
p
n
catsgroup
mgkg
npf
ab
mgkg
npf
ab
ns
p
p
fig
fig
black
dot
line
repres
initi
weight
cat
fcv
upstream
downstream
sequenc
tissu
fix
formalin
embed
paraffin
tissu
section
made
tissu
section
dewax
hydrat
wash
subject
antigen
retriev
use
trisodium
citrat
antigen
repair
solut
bbi
china
section
block
use
immunostain
blockingprimari
antibodi
dilut
buffer
incub
overnight
antifcv
antibodi
vmrd
usa
section
incub
hrplabel
rabbit
antifelin
secondari
antibodi
gibco
usa
dab
bbi
china
ad
color
develop
counterstain
hematoxylin
section
observ
microscop
olympu
japan
three
healthi
hors
immun
formaldehydeinactiv
fcv
mix
freund
complet
incomplet
adjuv
intramuscularli
time
total
sera
collect
serum
three
hors
neutral
titer
igg
serum
determin
neutral
assay
igg
neutral
titer
hors
sixth
immun
fig
igg
extract
satur
ammonium
sulfat
method
digest
pepsin
purifi
f
ab
pf
ab
fragment
obtain
prote
column
chromatographi
use
sdspage
assess
integr
igg
pf
ab
fragment
fig
puriti
pf
ab
fragment
purif
prote
column
fig
found
pf
ab
neutral
fcv
infect
vitro
surviv
rate
group
group
group
e
viral
load
trachea
lung
spleen
cat
significantli
differ
p
compar
group
treatment
group
c
two
cat
group
show
viru
shed
day
die
day
respect
surviv
rate
group
surviv
rate
group
rate
group
f
viral
load
trachea
lung
group
significantli
differ
group
day
p
n
catsgroup
mgkg
npf
ab
mgkg
npf
ab
ns
p
p
fig
c
red
dot
line
indic
copi
valu
greater
valu
cat
die
interpret
refer
color
figur
legend
reader
refer
web
version
articl
halfeffect
maxim
concentr
ec
pf
ab
fragment
fig
ifa
demonstr
pf
ab
effect
neutral
fcv
infect
vitro
emit
green
fluoresc
fig
found
challeng
dose
tcid
caus
anim
develop
diseas
differ
dose
pf
ab
given
prevent
group
day
challeng
treatment
group
three
day
challeng
monitor
rectal
temperatur
bodi
weight
cat
day
cat
receiv
pf
ab
whether
prevent
treatment
rectal
temperatur
weight
return
normal
earlier
control
group
npf
ab
red
n
fig
found
treatment
group
prevent
group
fig
f
significantli
p
higher
clinic
score
dpi
control
group
group
rtqpcr
use
detect
viral
shed
tissu
viral
load
prevent
treatment
group
found
cat
prevent
group
die
viru
shed
fig
b
viru
shed
associ
death
cat
treatment
group
fig
expect
antifcv
pf
ab
significantli
reduc
viral
load
trachea
lung
spleen
prevent
group
p
antifcv
pf
ab
significantli
reduc
tracheal
lung
viral
load
treatment
group
fig
f
found
pf
ab
significantli
decreas
viral
load
trachea
lung
spleen
observ
cat
inject
pf
ab
whether
prevent
therapeut
group
significantli
less
fcv
tissu
inject
npf
ab
chang
suggest
pf
ab
reduc
amount
fcv
differ
tissu
cat
fig
present
treatment
fcvinfect
cat
mainli
reliev
symptom
complet
curabl
acuteinfect
cat
although
mani
scholar
confirm
compound
inhibit
fcv
vitro
evid
show
excel
effect
cat
neutral
antibodi
provid
immedi
antivir
protect
regardless
diseas
state
cat
antibodi
prepar
hors
sera
advantag
low
cost
process
matur
produc
specif
antibodi
multipl
antigen
determin
remov
fc
fragment
igg
signific
allevi
allerg
reaction
anim
make
antibodi
safer
cat
importantli
polyclon
f
ab
fragment
recogn
bind
multipl
antigen
determin
fcv
may
avoid
potenti
antibodi
escap
moreov
f
ab
molecular
weight
igg
fab
fragment
highmolecularweight
igg
difficulti
enter
tissu
blood
vessel
result
delay
antigen
neutral
tissu
although
lowmolecularweight
fab
diffus
tissu
easili
blood
vessel
effect
neutral
antigen
rapid
remov
via
filtrat
kidney
impair
second
halflif
fab
vivo
less
f
ab
result
f
ab
superior
fab
dosag
time
studi
demonstr
hors
antifcv
serum
igg
neutral
titer
high
puriti
f
ab
fragment
purif
prote
column
next
found
f
ab
fragment
ec
ifa
found
specif
f
ab
fragment
antifcv
bind
fcv
importantli
demonstr
hors
antifcvspecif
f
ab
reduc
viral
load
viru
shed
outstand
prophylact
therapeut
fcv
perform
vivo
found
differ
dose
pf
ab
given
viral
challeng
could
reduc
clinic
symptom
mortal
infect
cat
found
viru
shed
amount
exceed
anim
die
notabl
obtain
data
druet
hennet
et
al
found
signific
correl
oral
ulcer
fcv
load
cat
may
also
use
predictor
surviv
anim
infect
fcv
given
certain
dose
pf
ab
viral
load
cat
trachea
lung
spleen
significantli
decreas
prevent
therapeut
group
p
organ
produc
felin
junction
adhes
molecul
fjama
fcvspecif
receptor
reduct
viral
load
viru
shed
demonstr
pf
ab
inhibit
prolifer
fcv
cat
immunohistochemistri
result
also
confirm
phenomenon
conclus
success
prepar
antifcv
f
ab
fragment
vivo
vitro
equin
igg
immun
healthi
hors
inactiv
fcv
antifcv
f
ab
fragment
prepar
hors
antibodi
reduc
viral
load
felin
trachea
lung
spleen
prevent
fcv
cat
prophylact
therapeut
experi
thu
hors
immun
inactiv
fcv
use
sourc
develop
f
ab
fragment
howev
detect
relat
immun
paramet
immun
increas
studi
confirm
use
prophylact
therapeut
agent
diseas
caus
fcv
zhang
lili
cao
guoy
dong
shushuai
yi
contribut
reagent
materialsanalysi
tool
zhand
cui
dengliang
li
wrote
paper
guixu
hu
yongkun
zhao
kai
wang
request
financi
support
author
read
approv
manuscript
present
work
support
project
topic
nation
key
r
plan
author
declar
conflict
interest
